

## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

Claims 1-23(Cancelled)

Claim 24 (Currently Amended): A method for inhibiting an anti-HLA alloimmune antibody response in a patient comprising the step of administering a therapeutically effective amount of a soluble 18KDa recombinant human CD40L consisting of amino acids 108 to 261 set forth in SEQ ID NO:1, containing the active binding site of CD40 and capable of binding thereto.

Claim 25 (Cancelled)

Claim 26 (Cancelled):

Claim 27 (Previously Presented): A method for inhibiting T cell function in an anti-HLA alloimmune response in a patient, comprising the step of administering a therapeutically effective amount of a soluble 18KDa recombinant human CD40L consisting of amino acids 108 to 261 of sequence set forth in SEQ ID NO:1 containing the active binding site of CD40 and capable of binding thereto.

Claim 28 (Cancelled)

Claim 29 (Cancelled)

Claim 30 (Currently Amended): A The method for inhibiting an anti-HLA alloimmune antibody response of claim 27, for treating or preventing a disease selected from the group consisting of systemic lupus erythematosus (SLE), Sjörger's syndrome, scleroderma myositis,

Raynaud's syndrome, type 1 diabetes, arthritis and rheumatoid arthritis, inflammatory bowel disease, uveitis, myasthenia gravis, multiple sclerosis, idiopathic thrombocytopenia purpura and graft vs host disease as well as allergies which are dependent on T cells, said method comprising the step of administering a therapeutically effective amount of a soluble 18KDa recombinant human CD40L consisting of amino acids 108 to 261 of sequence set forth in SEQ ID NO:1 containing the active binding site of CD40 and capable of binding thereto.

Claims 31-33 (Cancelled)

Claim 24 (new) The method of claim 30 wherein said disease is graft vs host disease.